A naturally occurring CXCL12gamma chemokine has potent anti-HIV-1 activity

FEATURES
The ability of chemokines to block HIV-1 infection has stimulated interest in the mechanism of their antiviral activity and potential use as therapeutic agents. Stromal cell-derived factor 1 (SDF-1)/CXCL12 is a member of the CXC chemokine family and has also been shown to block human immunodeficiency virus type 1 (HIV-1) infection. There are six splice variants of CXCL12 (alpha-gamma) which are identical in the first 88 amino acid residues and vary in the number of BBXB motifs.

Researchers at IU have analyzed the variants in terms of antiviral and chemotaxis activities. They have shown for the first time that CXCL12gamma is the most potent of the CXCL12 variants in inhibition of HIV-1 entry and demonstrates significantly reduced chemotaxis activity and small or absent effects on progenitor cell survival.

Ref: Journal of Virology, August 2007, p. 8140-8148, Vol. 81, No. 15

A naturally occurring splice variant of CXCL12/stromal cell-derived factor 1 is a potent human immunodeficiency virus type 1 inhibitor with weak chemotaxis and cell survival activities.

Altenburg JD, Broxmeyer HE, Jin Q, Cooper S, Basu S, Alkhatib G.

BENEFITS
* Naturally occurring, potent inhibitor of HIV-1 infection
* Downmodulates CXCR4 with weak chemotaxis
* Decrease viral load without affecting cellular physiology

Inventor(s): Ghalib Alkhatib, Ph.D.

Type of Offer: Licensing



« More Medical Patents

---